1)The Board considered and approved the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 30th June 2025. 2)The Board considered and approved ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250 and 0.2 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors of Transgene Biotek Ltd met and approved the unaudited standalone and consolidated financial results for the quarter ended 30 June 2025 (Q1 FY2026). The filing indicates this was a routine quarterly results announcement, with additional agenda items (point 2 onwards) truncated in the available source. No specific financial figures such as revenue, profit/loss, margins, or EPS are visible in the provided excerpt.
This is a standard quarterly compliance filing confirming board approval of results. Without the actual numbers, no meaningful impact on stock price or shareholder value can be inferred from this notice alone. Investors should look at the detailed financial results filing for Q1 FY2026 performance metrics.